Condition

Advanced Prostate Cancer clinical trials and research

• 15Clinical trials
• 46NIH research projects
• 14Countries

Newest Advanced Prostate Cancer clinical trials

All recruiting trials (15)

• DEC003M in Advanced Prostate Cancer

  This early-phase study tests DEC003M in adults with metastatic castration-resistant prostate cancer to see if it can be safely given and whether it shows signs of activity.

  Recruiting at 7 sites Phase 1 Hangzhou DAC Biotechnology Co., Ltd. · Beijing, Beijing Municipality and 6 other locations · NCT07657806

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• GDC-1261 in advanced or metastatic prostate cancer

  This study tests GDC-1261 to see if it is safe and how it behaves in people with advanced or metastatic prostate cancer who have progressed on prior therapy.

  Recruiting at 6 sites Phase 1/2 Genentech, Inc. · Scottsdale, Arizona and 5 other locations · NCT07567846

• QLC5508 and QLH12016 with other anti-tumor therapies in advanced prostate cancer

  This study tests QLC5508 and QLH12016, alone or with standard anti-tumor medicines, in men with advanced prostate cancer to see if they are safe and may help control the disease.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07198633

• HS-20093 plus HRS-5041 for advanced prostate cancer

  This phase Ib trial will test whether combining HS-20093, a B7-H3–targeted antibody-drug conjugate, with HRS-5041, an androgen receptor–targeting PROTAC, is safe and tolerable in men with metastatic castration-resistant prostate cancer who have progressed on prior hormonal therapy.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai · NCT07115446

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

• Registry collecting data on advanced prostate cancer imaging

  This study is collecting information on how advanced imaging techniques for prostate cancer can help doctors make better treatment decisions and improve patient outcomes.

  Recruiting at 4 sites Fundacio Puigvert · Leuven and 23 other locations · NCT06866782

• HS-10502 combination treatment for advanced solid tumors

  This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06769425

• Psychosocial intervention for managing symptoms in advanced cancer patients

  This study is testing a new telehealth program called ENGAGE to see if it can help people with advanced cancer manage their symptoms and improve their quality of life.

  Recruiting Duke University · Durham, North Carolina · NCT06555588

• Five Fraction Radiotherapy for Advanced Prostate Cancer

  This study is testing a new type of radiation therapy for men with advanced prostate cancer to see how safe it is and how it affects their quality of life and side effects.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06369246

• PSMA and FDG PET imaging for advanced prostate cancer

  This trial will test whether combining PSMA and FDG PET scans can better show tumor biology and help guide treatment for men with advanced prostate cancer.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06335914

• Detecting low PSMA prostate cancer using a special PET scan

  This study is testing a new type of PET scan to see if it can better detect advanced prostate cancer that has low PSMA levels or neuroendocrine features in patients.

  Recruiting at 2 sites Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06062745

• Testing HRS-5041 for advanced prostate cancer

  This study is testing a new drug called HRS-5041 to see if it is safe and effective for men with advanced prostate cancer who haven't responded to other treatments.

  Recruiting Phase 1 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT05942001

• Evaluating a new treatment for advanced prostate cancer

  This study is testing a new treatment for advanced prostate cancer to see how safe it is and if it helps patients feel better.

  Recruiting at 26 sites Phase 1 Genentech, Inc. · Scottsdale, Arizona and 25 other locations · NCT05800665

NIH-funded research (newest 40 of 46)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer

  A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.

  NIH research University of California at Davis · Davis, United States · NIH-11473215

• Boosting a tumor-suppressing enzyme to fight advanced prostate cancer

  A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11416822

• Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer

  A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11415651

• Genomic clues to guide therapy in advanced prostate cancer

  This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11411372

• DACH1-based test to predict therapy response in advanced prostate cancer

  A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.

  NIH research Ecogenome LLC · Doylestown, United States · NIH-11407343

• Understanding how doctors choose treatments to improve advanced prostate cancer care

  A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.

  NIH research Duke University · Durham, United States · NIH-11395342

• Biomarkers to guide Lu-PSMA therapy in advanced prostate cancer

  Researchers are testing a combination of blood-based markers and tumor imaging to see who will respond to Lu-PSMA therapy and why some patients develop resistance.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11394558

• Molecular brakes and targets for Trop-2 in advanced prostate cancer

  A cancer-focused research grant aims to understand how Trop-2 is controlled in advanced prostate cancer to find better treatment options.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11369786

• Targeting AR-driven prostate cancer by blocking PTGES3

  A patient-friendly study explores whether turning off a protein called PTGES3 can lower the cancer-promoting AR protein in advanced prostate cancer patients.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11367821

• How AR Inverse Agonists could help men with advanced prostate cancer

  Ages 21 and older with advanced prostate cancer may benefit from a new type of drug that changes how the androgen receptor drives cancer growth.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11365066

• ATAD2: a new target to treat advanced prostate cancer

  A new approach targets a protein called ATAD2 to help treat advanced prostate cancer, especially forms that resist standard therapies.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11361088

• PARP and Aurora kinase combo therapy for advanced prostate cancer

  A Mayo Clinic researcher is testing whether combining PARP inhibitors with Aurora kinase inhibitors can better treat advanced prostate cancer in men.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11334073

• Targeting epigenetic changes to overcome resistance in advanced prostate cancer

  Aimed at a form of prostate cancer that has stopped responding to common hormone therapies, this grant explores how epigenetic changes drive treatment resistance and how we might target them.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11333850

• GSTP1 as a target in advanced prostate cancer

  This grant explores whether blocking GSTP1 can slow or stop growth of advanced, treatment-resistant prostate cancer and improve how well other therapies work.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11330223

• Doctor-dispensed oral medicines for advanced prostate cancer and what that means for patients

  This project looks at how getting oral prostate cancer medicines directly from your doctor versus a pharmacy affects access, cost, safety, and whether patients take their pills as prescribed.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11295489

• New medicines that block both androgen production and the androgen receptor in advanced prostate cancer

  A new drug series aims to block the enzyme that makes androgens and the androgen receptor to help men with advanced, treatment-resistant prostate cancer.

  NIH research University of California at Davis · Davis, United States · NIH-11294346

• A new way to fight advanced prostate cancer

  A small NIH-funded project tests a novel approach to slow or stop advanced prostate cancer that has stopped responding to standard hormone therapies.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11284420

• Understanding advanced prostate cancer using mouse models

  Researchers are learning how BRCA1 and BRCA2 changes drive aggressive prostate cancer using specially bred mice to help find better treatments for men with treatment‑resistant disease.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11258968

• How doctors providing oral cancer medications affects patients with advanced prostate cancer

  This study is looking at how giving advanced prostate cancer patients their medications directly from their doctors' offices can make it easier for them to get and stick to their treatments, while also checking if this approach helps improve their health outcomes.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11240115

• Stopping a clock-related protein that helps advanced prostate cancer grow

  Researchers are testing drugs that block a circadian protein called Rev‑erbα to slow growth of advanced, treatment‑resistant prostate cancer.

  NIH research University of California at Davis · Davis, United States · NIH-11231218

• Drugs to turn back on a tumor-suppressor (PP2A) in advanced prostate cancer

  New small molecules aim to restore a tumor-suppressor enzyme called PP2A to help treat advanced prostate cancer that no longer responds to hormone therapies.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11196277

• Boosting CAR T cell therapy for advanced prostate cancer by blocking androgen signals

  This project looks at whether blocking androgen receptor signals can help a new STEAP1-targeted CAR T‑cell therapy work better for men with advanced, treatment‑resistant prostate cancer.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11181530

• Genetic markers that predict treatment response in advanced prostate cancer

  This project looks at whether tumor and inherited DNA changes can show which men with advanced prostate cancer are most likely to benefit from targeted drugs and immunotherapy.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11173720

• Improving advanced prostate cancer care for U.S. veterans

  This project will improve treatment access, safety, and the care experience for U.S. veterans with advanced prostate cancer.

  NIH research Veterans Health Administration · Ann Arbor, United States · NIH-11145702

• New Ways to Treat Advanced Prostate Cancer

  This research looks for new ways to stop advanced prostate cancer from growing by changing how cancer cells respond to treatment.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11133052

• Finding new ways to treat advanced prostate cancer

  This research looks for new treatments for advanced prostate cancer, especially forms that no longer respond to standard therapies.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11127423

• Understanding Trop-2 in advanced prostate cancer to find better treatments

  This project looks for new ways to treat advanced prostate cancer by understanding a specific protein called Trop-2.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11120973

• Targeting resistance mechanisms in advanced prostate cancer

  This study is looking at how advanced prostate cancer can change into a tougher form called neuroendocrine prostate cancer, and it's trying to find new ways to treat it to help patients feel better.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11094021

• Understanding how GSTP1 affects advanced prostate cancer

  This study is looking at a protein called GSTP1 to see how it affects advanced prostate cancer that doesn't respond to hormone therapy, and it aims to find out if targeting this protein could help improve treatment options for patients like you.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11090536

• New treatment targeting androgen production and receptors for advanced prostate cancer

  This study is exploring a new way to treat advanced prostate cancer by blocking certain processes that help the cancer grow, which could lead to better results for patients who haven't had success with current treatments.

  NIH research University of California at Davis · Davis, United States · NIH-11056165

• Understanding how IGFBP3 affects resistance to Olaparib in advanced prostate cancer

  This study is looking at how a protein called IGFBP3 affects advanced prostate cancer's ability to resist a treatment called Olaparib, with the goal of finding better ways to help patients respond to this therapy.

  NIH research VA Northern California Health Care Sys · Mather, United States · NIH-11034085

• Investigating hormone signaling and protein synthesis in advanced prostate cancer

  This study is looking at how certain hormones and proteins affect advanced prostate cancer, especially a tough type called androgen receptor-low castration resistant prostate cancer, to find new ways to help treat patients better.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11007160

• Targeting a disrupted circadian regulator to treat advanced prostate cancer

  This study is looking at how a specific protein called Rev-erbα affects advanced prostate cancer that doesn't respond to usual treatments, and it will test a new way to block this protein to see if it can help slow down the cancer and improve patient outcomes.

  NIH research University of California at Davis · Davis, United States · NIH-10993125

• Targeting Wnt5A signaling to improve treatment for advanced prostate cancer

  This study is looking at how a specific signaling process called Wnt5A affects advanced prostate cancer that doesn't respond to common treatments, with the goal of finding new ways to make these treatments work better for patients.

  NIH research University of California at Davis · Davis, United States · NIH-10986078

• Targeting steroid sulfatase to treat advanced prostate cancer

  This study is looking at how a protein called steroid sulfatase affects advanced prostate cancer that doesn't respond to common treatments, and it's working on new medicines that could help lower hormone levels and improve options for patients dealing with this tough situation.

  NIH research University of California at Davis · Davis, United States · NIH-10977364

• Investigating how MED1 affects androgen receptor activity in advanced prostate cancer

  This study is looking at a tough type of prostate cancer and how a protein called MED1 works with a hormone receptor that helps the cancer grow, with the goal of finding new treatments that could help patients by blocking this process.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10977344

• Investigating how certain drugs can block the effects of the androgen receptor in advanced prostate cancer.

  This study is looking at how certain new medications can help treat advanced prostate cancer, especially when other treatments aren't working anymore, to find better ways to slow down tumor growth and improve care for patients like you.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-10939509

• Exploring a new treatment target for advanced prostate cancer

  This study is looking at a new way to treat advanced prostate cancer that doesn't respond to regular treatments by testing a special type of medicine that targets a protein called ATAD2, with the hope of finding better options for patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-10902612

• Understanding how doctors make decisions for advanced prostate cancer treatment

  This study looks at how doctors decide on treatments for patients with advanced prostate cancer, focusing on what influences their choices and how those choices affect patient care, with the hope of finding ways to improve treatment for everyone facing this tough diagnosis.

  NIH research Duke University · Durham, United States · NIH-10897019

• Improving prostate cancer care for US veterans

  This study is looking to help Vietnam Veterans with metastatic prostate cancer by figuring out what makes it hard for them to get the best care and how their treatment experience can be improved.

  NIH research Veterans Health Administration · Ann Arbor, United States · NIH-10883551

Related topics

Quick answers

How many Advanced Prostate Cancer clinical trials are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in United States (6 trials), China (5 trials), Canada (2 trials), France (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 2: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →